Neuropeptide Y and ATP interact to control renovascular resistance in the rat

Journal of the American Society of Nephrology

Volumn 10, Issue 6, 1999, Pages 1179-1185

  Oberhauser, Vitus ^a   Vonend, Oliver ^a   Rump, Lars Christian ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; PHENTOLAMINE; SURAMIN;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; KIDNEY NERVE; KIDNEY PERFUSION; KIDNEY VASCULAR RESISTANCE; MALE; NERVE STIMULATION; NEUROTRANSMISSION; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; SYMPATHETIC TONE; VASOCONSTRICTION;

EID: 0032996241     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Insel PA: Adrenergic receptors: Evolving concepts and clinical implications. N Engl J Med 334: 580-585, 1996
2. Lundberg JM: Pharmacology of cotransmission in the autonomic nervous system: Integrative aspects on amines neuropeptides adenosine triphosphate amino acids and nitric oxide. Pharmacol Rev 48: 113-178, 1996
3. Burnstock G: Development and perspectives of the purinoceptor concept. J Auton Pharmacol 16: 295-302, 1996
4. Thulin T, Erlinge D: Neuropeptide Y and hypertension. Nutrition 11: 495-497, 1995
5. Bald M, Gerigk M, Rascher W: Elevated plasma concentrations of neuropeptide Y in children and adults with chronic and terminal renal failure. Am J Kidney Dis 30: 23-27, 1997
6. Bischoff A, Avramidis P, Erdbrügger W, Münter K, Michel MC: Receptor subtypes Y1 and Y5 are involved in the renal effects of neuropeptide Y. Br J Pharmacol 120: 1335-1343, 1997
7. Von Kügelgen I, Krumme B, Schaible U, Schollmeyer PJ, Rump LC: Vasoconstrictor responses to the P2X-receptor agonist β γ-methylene-L-ATP in human cutaneous and renal blood vessels. Br J Pharmacol 116: 1932-1936, 1995
8. Churchill PC, Ellis VR: Pharmacological characterization of the renovascular P2-purinergic receptor. J Pharmacol Exp Ther 265: 334-338, 1993
9. Navar LG, Inscho EW, Majid SA, Imig JD, Harrsion-Bernard LM, Mitchell KD: Paracrine regulation of the renal microcirculation. Physiol Rev 76: 425-536, 1996
10. Inscho EW, Cook AK, Mui VY, Miller J: Direct assessment of renal microvascular responses to P2-purinoceptor agonists. Am J Physiol 43: F718-F727, 1998
11. Bischoff A, Michel MC: Renal effects of neuropeptide Y. Pflügers Arch 435: 443-453, 1998
12. Bohmann C, Rump LC, Schaible U, von Kügelgen I: α-Adrenoceptor modulation of norepinephrine and ATP release in isolated kidneys of spontaneously hypertensive rats. Hypertension 25: 1224-1231, 1995
13. Rump LC, Bohmann C, Schwertfeger E, Krumme B, von Kügelgen I, Schollmeyer P: Extracellular ATP in the human kidney: Mode of release and vascular effects. J Auton Pharmacol 16: 371-376, 1996
14. Schwartz DD, Malik KU: Renal periarterial nerve stimulation-induced vasoconstriction at low frequencies is primarily due to release of a purinergic transmitter in the rat. J Pharmacol Exp Ther 250: 764-771,1989
15. 2 inhibits noradrenaline release and purinergic pressor responses to renal nerve stimulation at 1 Hz in isolated kidneys of young spontaneously hypertensive rats. J Hypertens 8: 897-908, 1990
16. Rump LC, Wilde K, Bohmann C, Schollmeyer P: Effects of the novel dopamine DA2-receptor agonist carmoxirole (EMD 45609) on noradrenergic and purinergic neurotransmission in rat isolated kidney. Naunyn-Schmiedebergs Arch Pharmacol 345: 300-308, 1992
17. Todorov LD, Mihaylowa-Todorova S, Westfall TD, Sneddon P, Kennedy C, Bjur RA, Westfall DP: Neuronal release of soluble nucleotidases and their role in neurotransmitter inactivation. Nature 387: 76-79, 1997
18. Rudolf K, Eberlein W, Engel W, Wieland HA, Willim KD, Entzeroth M, Wienen W, Beck-Sickinger AG, Doods HN: The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur J Pharmacol 271: R11-R13, 1994
19. 2-adrenoceptors in isolated perfused kidneys of spontaneously hypertensive rats. Cardiovasc Res 30: 857-865, 1995
20. 2-receptor modulation of noradrenergic neurotransmission in rat kidney. Br J Pharmacol 121: 1255-1262, 1997
21. Jocks T, Zahner G, Helmchen U, Kneissler U, Stahl RA: Antibody and complement reduce renal hemodynamic function in isolated perfused rat kidney. Am J Physiol 270: F179-F185, 1996
22. DiBona GF, Kopp UC: Neural control of renal function. Physiol Rev 77: 175-197, 1997
23. Liu L, Barajas L: Nitric oxide synthase immunoreactive neurons in the rat kidney. Neurosci Lett 161: 145-148, 1993
24. Oellerich FW, Malik KU: Neuropeptide Y modulates the vascular responses to periarterial nerve stimulation primarily by a postjunctional action in the isolated perfused rat kidney. J Pharmacol Exp Ther 266: 1321-1329, 1993
25. 2, NPY and angiotensin II receptors. Naunyn-Schmiedebergs Arch Pharmacol 340: 379-385, 1989
26. Chen H, Bischoff R, Schäfers RF, Wambach G, Philipp T, Michel MC: Vasoconstriction of rat renal interlobar arteries by noradrenaline and neuropeptide Y. J Auton Pharmacol 17: 137-146, 1997
27. Westfall TC, Yang CL, Curfman-Falvey M: Neuropeptide Y-ATP interactions at the vascular sympathetic neuroeffector junction. J Cardiovasc Pharmacol 26: 682-687, 1995
28. Han S, Yang CL, Chen X, Naes L, Cox BF, Westfall T: Direct evidence for the role of neuropeptide Y in sympathetic nerve stimulation-induced vasoconstriction. Am J Physiol 274: H290-H294, 1998
29. Rump LC, Riess M, Schwertfeger E, Michel MC, Bohmann C, Schollmeyer P: Prejunctional neuropeptide Y receptors in human kidney and atrium. J Cardiovasc Pharmacol 29: 656-661, 1997
30. Smith AB, Cunnane TC: Omega-GVIA-resistant neurotransmitter release from postganglionic sympathetic nerves in the guinea-pig vas deferens and its modulation by presynaptic receptors. Br J Pharmacol 123: 167-172, 1998
31. Lundberg JM, Modin A: Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226. Br J Pharmacol 116: 2971-2982, 1995
32. Bischoff A, Freund A, Michel MC: The Y1 antagonist BIBP 3226 inhibits potentiation of methoxamine-induced vasoconstriction by neuropeptide Y. Naunyn-Schmiedebergs Arch Pharmacol 356: 635-640, 1997